{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:18Z","timestamp":1793442678644,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H05259"],"award-info":[{"award-number":["21H05259"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02645"],"award-info":[{"award-number":["21H02645"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02201"],"award-info":[{"award-number":["24K02201"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115392","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:37:16Z","timestamp":1790177836000},"page":"115392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Structure-biodistribution relationships of chemically and physically modified albumin: a systematic approach to organ-specific drug delivery"],"prefix":"10.1016","volume":"399","author":[{"given":"Mirai","family":"Nakakita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maichi","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ikeda-Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor T.G.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Takanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115392_bb0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/bs.apcsb.2020.08.003","article-title":"Serum albumin: clinical significance of drug binding and development as drug delivery vehicle","volume":"123","author":"Tayyab","year":"2021","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.jconrel.2026.115392_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural basis of the drug-binding specificity of human serum albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115392_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol. Cell. Ther."},{"key":"10.1016\/j.jconrel.2026.115392_bb0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115392_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2026.115392_bb0030","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115392_bb0035","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1517\/14656561003796562","article-title":"Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel","volume":"11","author":"Petrelli","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115392_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2005.00487.x","article-title":"Insulin detemir: a new basal insulin analogue","volume":"8","author":"Soran","year":"2006","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.115392_bb0045","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1248\/cpb.c21-01024","article-title":"The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors","volume":"70","author":"Ishima","year":"2022","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"key":"10.1016\/j.jconrel.2026.115392_bb0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2015.06.006","article-title":"The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery","volume":"211","author":"Bern","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115392_bb0055","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1016\/j.bbagen.2013.04.036","article-title":"Redox properties of serum albumin","volume":"1830","author":"Anraku","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2026.115392_bb0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2013.07.013","article-title":"Review: glycation of human serum albumin","volume":"425","author":"Anguizola","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jconrel.2026.115392_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/biom9110705","article-title":"Conformation and aggregation of human serum albumin in the presence of green tea polyphenol (EGCg) and\/or palmitic acid","volume":"9","author":"Sun","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.115392_bb0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2110-5820-3-4","article-title":"Specific antioxidant properties of human serum albumin","volume":"3","author":"Taverna","year":"2013","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.jconrel.2026.115392_bb0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2133\/dmpk.21.140","article-title":"The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP)","volume":"21","author":"Iwao","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115392_bb0080","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1618291114","article-title":"Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury","volume":"114","author":"Pyzik","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.115392_bb0085","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bbadis.2007.09.001","article-title":"The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs","volume":"1772","author":"Nagai","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.jconrel.2026.115392_bb0090","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1248\/bpb.b13-00553","article-title":"Characterization of protamine uptake by opossum kidney epithelial cells","volume":"36","author":"Nagai","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2026.115392_bb0095","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1681\/ASN.2010050492","article-title":"Cubilin is essential for albumin reabsorption in the renal proximal tubule","volume":"21","author":"Amsellem","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jconrel.2026.115392_bb0100","doi-asserted-by":"crossref","first-page":"24544","DOI":"10.1016\/S0021-9258(18)35799-5","article-title":"Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism","volume":"267","author":"Schnitzer","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115392_bb0105","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1021\/acsami.1c03065","article-title":"Evidence for delivery of abraxane via a denatured-albumin transport system","volume":"13","author":"Hama","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.115392_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0580","article-title":"An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics","volume":"12","author":"Bern","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115392_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120296","article-title":"Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-a on activated macrophages to treat rheumatoid arthritis","volume":"258","author":"Gong","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115392_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.niox.2010.05.002","article-title":"One-step preparation of S-nitrosated human serum albumin with high biological activities","volume":"23","author":"Ishima","year":"2010","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jconrel.2026.115392_bb0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/12.6.439","article-title":"Crystal structure of human serum albumin at 2.5 A resolution","volume":"12","author":"Sugio","year":"1999","journal-title":"Protein Eng."},{"key":"10.1016\/j.jconrel.2026.115392_bb0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1570-9639(03)00002-5","article-title":"Isolation and characterization of denatured serum albumin from rats with endotoxicosis","volume":"1646","author":"Bito","year":"2003","journal-title":"Biochim. Biophy. Acta Proteins Proteomics"},{"key":"10.1016\/j.jconrel.2026.115392_bb0135","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/ar500190q","article-title":"Nanoparticle\u2013cell interactions: molecular structure of the protein corona and cellular outcomes","volume":"47","author":"Fleischer","year":"2014","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2026.115392_bb0140","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1016\/S0021-9258(18)53212-9","article-title":"High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors","volume":"268","author":"Schnitzer","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115392_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9258(19)81445-X","article-title":"Removal of fatty acids from serum albumin by charcoal treatment","volume":"242","author":"Chen","year":"1967","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115392_bb0150","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1021\/acsabm.1c00110","article-title":"Reduction-responsive and multidrug deliverable albumin nanoparticles: an antitumor drug to abraxane against human pancreatic tumor-bearing mice","volume":"4","author":"Hirakawa","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2026.115392_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202501853","article-title":"Arming abraxane with cationic spermidine conjugate and homologous cell membrane for enhanced triple-negative breast cancer therapy","volume":"15","author":"Zheng","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.115392_bb0160","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.bbapap.2007.09.001","article-title":"Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin","volume":"1774","author":"Iwao","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2026.115392_bb0165","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/mp500394v","article-title":"Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy","volume":"12","author":"Qi","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115392_bb0170","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2016.01.046","article-title":"Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors","volume":"225","author":"Byeon","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115392_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1034\/j.1600-0676.2001.210504.x","article-title":"Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA)","volume":"21","author":"Beljaars","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.jconrel.2026.115392_bb0180","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbapap.2006.01.011","article-title":"Oxidation of Arg-410 promotes the elimination of human serum albumin","volume":"1764","author":"Iwao","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2026.115392_bb0185","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbapap.2008.11.022","article-title":"Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin","volume":"1794","author":"Iwao","year":"2009","journal-title":"Biochim. Biophy. Acta Proteins Proteomics"},{"key":"10.1016\/j.jconrel.2026.115392_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1329636","article-title":"GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs","volume":"15","author":"Ji","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115392_bb0195","first-page":"3445","article-title":"Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator","volume":"11","author":"Chen","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115392_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040728","article-title":"Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation","volume":"14","author":"Cho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115392_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijpharm.2014.04.010","article-title":"Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?","volume":"468","author":"Li","year":"2014","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:44:24Z","timestamp":1793439864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0168365926007960"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115392","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-biodistribution relationships of chemically and physically modified albumin: a systematic approach to organ-specific drug delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115392"}}